First‐in‐human assessment of safety and pharmacokinetics of EP9001A:an anti‐nerve growth factor antibody for chronic pain treatment

Documenti analoghi

• Psilocybin as a novel treatment for chronic pain
  di: Tate Askey, et al.
  Pubblicazione: (2024)
• Evaluation of the effect of CYP2D6 and OCT1 polymorphisms on the pharmacokinetics of tramadol: Implications for clinical safety and dose rationale in paediatric chronic pain
  di: Paul Healy, et al.
  Pubblicazione: (2024)
• Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E‐based antibody–drug conjugates
  di: Hsuan‐Ping Chang, et al.
  Pubblicazione: (2024)
• Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
  di: C. Hu, et al.
  Pubblicazione: (2025)
• Early clinical pharmacology evaluation of the novel anti‐inflammatory macrolide, glasmacinal (EP395): tolerability, pharmacokinetics and drug interactions
  di: Dave Singh, et al.
  Pubblicazione: (2026)